Open an account

Instil Bio

TIL · NASDAQ

$5.94+$0.15 (+2.59%)TodayMarket closed ·
Prev close $5.79

About TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 17 full-time employees. The company went IPO on 2021-03-19. The firm seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.

Employees
17
Headquarters
Dallas, Texas
Listed
Mar 19, 2021
Sector
Health Care
Industry
Biotechnology
Website
instilbio.com

TIL key statistics

Market cap
40.28M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
29.69K
Volume
100.16K
Open price
$5.88
High today
$6.19
Low today
$5.85
52 Week high
$20.32
52 Week low
$5.62

Instil Bio (TIL) at a glance

Instil Bio (TIL) last traded at $5.94, with a market cap of 40.28M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.85 and $6.19. The current price is 1.5% above the day's low and 4.0% below its high.

Volume so far is 100.16K shares, above the average of 29.69K shares a day.

Over the past year Instil Bio has ranged from $5.62 to $20.32, and now sits 2% of the way up that range.

Instil Bio met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.63 per share against an estimate of -$0.4343.

The average analyst price target is $7.14, 20.2% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 2 analystsAvg $7.14
Low
$7.07
Now
$5.94
High
$7.35

TIL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 33.5% on average.

  1. Q3 FY24: reported -$3.54 per share against an estimate of -$2.13
  2. Q4 FY24: reported -$1.82 per share against an estimate of -$3.25
  3. Q1 FY25: reported -$4.32 per share against an estimate of -$2.61
  4. Q2 FY25: reported -$3.24 per share against an estimate of -$2.53
  5. Q3 FY25: reported -$2.01 per share against an estimate of -$2.38
  6. Q4 FY25: reported -$1.21 per share against an estimate of -$2.05
  7. Q1 FY26: reported -$0.62 per share against an estimate of -$0.5959
  8. Q2 FY26: reported -$0.63 per share against an estimate of -$0.4343

TIL news

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

  • Avi Kapoor

    Dow Jumps Over 400 Points; US Services Activity Falls In December

Similar companies

Companies in the same industry as Instil Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.